Metipranolol

Summary

Metipranolol (CHEMBL1291) is an approved small-molecule β-adrenergic antagonist (ATC S01ED04); indicated across 1 condition including glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01ED04 (+1 more)
• Indications: 1 condition
• Chemistry: 309.4 Da · C17H27NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1291
Name	Metipranolol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31477
ChEBI	CHEBI:6897
ATC	S01ED04, S01ED54
Molecular formula	C17H27NO4
Molecular weight	309.4
InChIKey	BQIPXWYNLPYNHW-UHFFFAOYSA-N

SMILES: CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O

IUPAC name: [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate

ChEBI definition: 3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.

Pharmacological roles (ChEBI): β-adrenergic antagonist, anti-arrhythmia drug, antihypertensive agent, antiglaucoma drug.

Also known as: BM-01.004, BM-01004, BM01.004, D, l-metipranolol, Glauline, Metipranolol, VUAB-6453, VUAB6453, VUAB6453 (SPOFA), metipranolol, SID29215465

Parent form; salt/anhydrous children: CHEMBL1200947

Patent coverage: 2,128 distinct patent families (8,997 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,992 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).